NCT02668185

Neuropeptide Treatment for Hot Flushes During the Menopause

Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Imperial College London · Academic / Other
• Sex: Female
• Age: 40 Years – 62 Years
• Healthy volunteers: Accepted

Summary

Placebo-controlled, double-blinded, cross-over clinical trial of a new investigational product

Detailed description

Double-blinded, placebo-controlled, 2-way crossover study in 30 menopausal women with untreated hot flushes treated with a neurokinin 3 receptor (NK3R) antagonist Aims: To investigate whether an NK3R antagonist can reduce menopausal flushing Treatment: 4 weeks administration of active drug and placebo in random order

Conditions

• Menopausal Flushing

Interventions

Type	Name	Description
DRUG	NK3R antagonist - AZD4901	Neurokinin 3 receptor antagonist
DRUG	Placebo	Placebo

Timeline

• Start date: 2016-02-01
• Primary completion: 2017-01-01
• Completion: 2017-01-01
• First posted: 2016-01-29
• Last updated: 2021-05-03
• Results posted: 2021-05-03

Locations

1 site across 1 country: United Kingdom